CareDx (NASDAQ:CDNA) Trading Down 5.5% - Time to Sell?

CareDx, Inc (NASDAQ:CDNA - Get Free Report) shares fell 5.5% on Tuesday . The company traded as low as $23.81 and last traded at $23.53. 271,391 shares traded hands during trading, a decline of 68% from the average session volume of 836,722 shares. The stock had previously closed at $24.91.

Analyst Ratings Changes

A number of research firms have recently weighed in on CDNA. HC Wainwright reaffirmed a "neutral" rating and set a $26.00 price target on shares of CareDx in a report on Tuesday, January 14th. BTIG Research cut their price target on CareDx from $40.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, November 5th. Finally, Wells Fargo & Company raised CareDx from an "underweight" rating to an "equal weight" rating and cut their price target for the company from $28.00 to $24.00 in a report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $28.33.

CareDx Price Performance

The stock has a market cap of $1.31 billion, a P/E ratio of -9.07 and a beta of 1.87. The company has a fifty day moving average of $22.69 and a 200 day moving average of $25.32.

Insider Buying and Selling at CareDx

In other CareDx news, Director Peter Maag sold 5,000 shares of the company's stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the transaction, the director now owns 330,024 shares of the company's stock, valued at approximately $8,250,600. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CDNA. CWM LLC grew its position in CareDx by 560.1% during the 3rd quarter. CWM LLC now owns 7,604 shares of the company's stock worth $237,000 after purchasing an additional 6,452 shares in the last quarter. Creative Planning purchased a new position in CareDx during the 3rd quarter worth approximately $204,000. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new position in CareDx during the 3rd quarter worth approximately $206,000. nVerses Capital LLC grew its position in CareDx by 175.0% during the 3rd quarter. nVerses Capital LLC now owns 3,300 shares of the company's stock worth $103,000 after purchasing an additional 2,100 shares in the last quarter. Finally, Harbour Capital Advisors LLC purchased a new position in CareDx during the 3rd quarter worth approximately $373,000.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.